Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?

Area of Science:

• Cardiology
• Pharmacology
• Exercise Physiology

Background:

• Heart failure (HF) significantly impairs exercise capacity, leading to high morbidity and mortality.
• While HF therapies improve survival, exercise intolerance remains a debilitating symptom.
• Skeletal muscle dysfunction and cardiovascular pathology contribute to HF-related exercise intolerance.

Purpose of the Study:

• To review the mechanisms of exercise intolerance in HF.
• To explore potential SGLT2 inhibitor-mediated effects on HF exercise intolerance.
• To summarize current evidence on SGLT2 inhibitors and exercise capacity in HF.

Main Methods:

• Literature review of pathophysiological mechanisms of HF exercise intolerance.
• Analysis of SGLT2 inhibitor effects on skeletal muscle and cardiovascular function.
• Synthesis of clinical trial data on SGLT2 inhibitors and exercise parameters in HF.

Main Results:

• SGLT2 inhibitors have shown significant cardiovascular benefits.
• Mechanisms linking SGLT2 inhibitors to improved exercise capacity in HF are under investigation.
• Existing studies provide an overview of SGLT2 inhibitor effects on relevant clinical outcomes.

Conclusions:

• SGLT2 inhibitors represent a promising therapeutic avenue for improving exercise capacity in HF.
• Further research is needed to fully elucidate the impact of SGLT2 inhibitors on exercise intolerance in chronic HF.
• Understanding these effects can guide future treatment strategies for HF patients.